Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 95 (3), 441-6

Thrombocytopenia in Term Infants: A Population-Based Study


Thrombocytopenia in Term Infants: A Population-Based Study

S Sainio et al. Obstet Gynecol.


Objective: To assess the prevalence and causes of thrombocytopenia among full-term infants.

Methods: We conducted a 1-year, population-based surveillance study involving all full-term infants (at least 37 weeks' gestation) born to native Finnish women in Helsinki. In cases of thrombocytopenia (cord platelet count less than 150 x 10(9)/L) clinical risk factors were evaluated and immunologic studies were performed on both parents and on the infant; 95% confidence intervals (CIs) were calculated on the basis of binomial distribution.

Results: Platelet counts were done in cord blood from 4,489 infants, 84.9% of the study population. Eighty-nine infants had platelet counts below 150 x 10(9)/L (2.0%; 95% CI 1.5, 2.3) in cord blood and 11 were less than 50 x 10(9)/L (0.24%; 95% CI 0.10, 0.38). All causes of clinically important thrombocytopenia, those presenting with bleeding and requiring treatment, were related to fetomaternal alloimmune thrombocytopenia. The incidence of severe alloimmune thrombocytopenia was one in 1500 live births and one in 900 of all thrombocytopenia. An immunologic mechanism was involved in ten of 65 (15.4%; 95% CI 6.6, 24.2) infants studied and in four of 15 (26.7%; 95% CI 4.3, 49.1) cases of severe thrombocytopenia.

Conclusion: Immunologic studies should be considered in all cases of severe neonatal thrombocytopenia for careful monitoring and prevention of potentially severe complications in subsequent pregnancies.

Similar articles

  • Maternal Thrombocytopenia at Term: A Population-Based Study
    S Sainio et al. Acta Obstet Gynecol Scand 79 (9), 744-9. PMID 10993097.
    Women with gestational thrombocytopenia do not require alteration of their treatment. Fetal blood sampling is not considered necessary when thrombocytopenia is discovered …
  • Neonatal Alloimmune Thrombocytopenia: Antenatal Management
    RM Silver et al. Am J Obstet Gynecol 182 (5), 1233-8. PMID 10819864.
    Severe fetal alloimmune thrombocytopenia does not always occur in subsequent fetuses. Thus either fetal antigen status or platelet counts or both of these are necessary t …
  • Neonatal Thrombocytopenia in the Hypertensive Disorders of Pregnancy
    RF Burrows et al. Obstet Gynecol 76 (2), 234-8. PMID 2371026.
    Infants of hypertensive mothers are at risk for a platelet count below 150 x 10(9)/L. To define this risk and assess maternal factors influencing the prevalence of neonat …
  • Antenatal Interventions for Fetomaternal Alloimmune Thrombocytopenia
    R Rayment et al. Cochrane Database Syst Rev (1), CD004226. PMID 15674934. - Review
    There are insufficient data from randomised controlled trials to determine the optimal antenatal management of fetomaternal alloimmune thrombocytopenia. Future trials sho …
  • The Management of Alloimmune Neonatal Thrombocytopenia
    VS Blanchette et al. Baillieres Best Pract Res Clin Haematol 13 (3), 365-90. PMID 11030040. - Review

    Neonatal alloimmune thrombocytopenia (NAITP), defined as thrombocytopenia (platelet count < 150 x 10(9)/l) due to transplacentally acquired maternal platelet alloantib

See all similar articles

Cited by 7 PubMed Central articles

See all "Cited by" articles

Publication types

LinkOut - more resources